Researchers of a study revealed that patients with atopic dermatitis (AD) prioritize treatments that effectively control itch while minimizing adverse event risks. The study highlighted various treatment options for moderate-to-severe AD, including systemic therapies, biologics, and newer options like Janus kinase inhibitors and monoclonal antibodies.

The comprehensive discrete choice study, conducted online in June 2023, involved US patients aged 18 or older with at least a year-long diagnosis of AD and inadequate responses to topical treatments. Researchers identified key treatment attributes through literature review, patient interviews, and clinical opinions. They then presented 300 patients with 12 choice tasks, each containing two hypothetical AD treatment profiles. Results showed that itch control was the most important attribute (relative importance [RI], 38%), followed by cancer risk (RI, 23%), respiratory infection risk (RI, 18%), and heart problems risk (RI, 11%). Sustained skin appearance improvement, blood test frequency, and administration frequency/mode were the least important.

Reference: McCormick B. Patients With AD Prioritize Itch Control in Treatment Preferences. AJMC. Published May 14, 2024. Accessed May 29, 2024. https://www.ajmc.com/view/patients-with-ad-prioritize-itch-control-in-treatment-preferences